{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:04:14Z","timestamp":1778796254977,"version":"3.51.4"},"reference-count":7,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Human Gene Therapy"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1089\/hum.2024.29268.bfs","type":"journal-article","created":{"date-parts":[[2024,4,16]],"date-time":"2024-04-16T15:23:50Z","timestamp":1713281030000},"page":"215-218","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":8,"title":["Orchard Therapeutics Gains First U.S. Approval for a Metachromatic Leukodystrophy Gene Therapy"],"prefix":"10.1177","volume":"35","author":[{"given":"Alex","family":"Philippidis","sequence":"first","affiliation":[{"name":"Mary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,4,16]]},"reference":[{"key":"e_1_3_1_2_2","unstructured":"Orchard Therapeutics. Orchard Therapeutics Receives FDA Approval of Lenmeldy\u2122 (Atidarsagene Autotemcel) the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S. March 18 2024. Available from: https:\/\/ir.orchard-tx.com\/news-releases\/news-release-details\/orchard-therapeutics-receives-fda-approval-lenmeldytm [Last accessed: March 19 2024]."},{"key":"e_1_3_1_3_2","unstructured":"Kansteiner M. Takeda Winds Down Manufacturing and R&D Operations in Austria after Gene Therapy Pivot Plots 190 Layoffs. March 13 2024. Available from: https:\/\/www.fiercepharma.com\/pharma\/following-gene-therapy-pivot-takeda-says-its-winding-down-manufacturing-and-rd-operations [Last accessed: March 16 2024]."},{"key":"e_1_3_1_4_2","unstructured":"CRISPR Therapeutics. Prospectus Supplement February 13 2024. Available from: https:\/\/ir.crisprtx.com\/static-files\/3266040b-3f7a-47f0-830b-24c2e605d751 [Last accessed: March 11 2024]."},{"key":"e_1_3_1_5_2","unstructured":"CRISPR Therapeutics. CRISPR Therapeutics Announces $280 Million Registered Direct Offering. February 13 2024. Available from: https:\/\/ir.crisprtx.com\/news-releases\/news-release-details\/crispr-therapeutics-announces-280-million-registered-direct [Last accessed: March 11 2024]."},{"key":"e_1_3_1_6_2","unstructured":"enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress. March 11 2024. Available from: https:\/\/engene.com\/engene-reports-first-quarter-2024-financial-results-and-recent-corporate-progress\/ [Last accessed: March 11 2023]."},{"key":"e_1_3_1_7_2","unstructured":"REGENXBIO. REGENXBIO Announces New Positive Initial Efficacy Data from AFFINITY Duchenne\u00ae Trial. March 5 2024. Available from: https:\/\/regenxbio.gcs-web.com\/news-releases\/news-release-details\/regenxbio-announces-new-positive-initial-efficacy-data-affinity [Last accessed: March 13 2024]."},{"key":"e_1_3_1_8_2","unstructured":"Asgard Therapeutics. Asgard Therapeutics Announces \u20ac30 Million Series A Financing to Advance its First-in-Class In Vivo Cell Reprogramming Platform for Immuno-oncology. March 14 2024. Available from: https:\/\/www.asgardthx.com\/asgard-therapeutics-announces-e30-million-series-a-financing-to-advance-its-first-in-class-in-vivo-cell-reprogramming-platform-for-immuno-oncology\/#_edn3 [Last accessed: March 16 2024]."}],"container-title":["Human Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1089\/hum.2024.29268.bfs","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.29268.bfs","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1089\/hum.2024.29268.bfs","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:57:16Z","timestamp":1777449436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1089\/hum.2024.29268.bfs"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":7,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1089\/hum.2024.29268.bfs"],"URL":"https:\/\/doi.org\/10.1089\/hum.2024.29268.bfs","relation":{},"ISSN":["1043-0342","1557-7422"],"issn-type":[{"value":"1043-0342","type":"print"},{"value":"1557-7422","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}